Hartford Business.com
September 02, 2010
Browse News by Topic
- Agriculture
- Architecture
- Banking & Finance
- Biotechnology
- Construction
- Economy
- Education
- Energy
- Government & Politics
- Health Care
- Insurance
- Legal
- Manufacturing
- Media & Marketing
- Nonprofits
- Real Estate
- Restaurant & Food
- Retail
- Small Business
- Technology
- Telecom
- Tourism
- Transportation
Data Products
To Do List
- Subscribe to the HBJ
- Signup for HBJ Today & eNews
- Get In The HBJ (PDF)
- View HBJ Business Profiles
- Get Your Company Listed in the HBJ
- View Book Of Lists Info
- Send Us A Press Release
- Add a Calendar Item
- Advertise in the HBJ
- Register for the CT Business Expo
- Update your account information
Awards & Events
- View Supplements Online
- Photo Gallery
- Health Care Heroes
- Diversity
- Best Places to Work
- eTechnology Summit and Strateg-e Awards
- Women in Business
- CT Business Expo
- Business Champions
- Nonprofit Heroes
- Small Business Awards
- Business Energy Summit
- 40 Under Forty
- CFO of the Year
- Lifetime Achievement
New Haven-based Achillion Pharmaceuticals Inc. said its stock faces delisting from the Nasdaq because its shareholder equity has fallen below minimum levels to stay on the exchange.
Achillion, developing small-molecule drugs to treat such blood-borne diseases as hepatitis and HIV, said its stockholders' equity at Sept. 30 was $7.2 million. Nasdaq requires a $10 million minimum equity level.
Achillion said it will submit a definitive plan to return to compliance.
This article does not currently have any comments